Stromedix

Stromedix, Inc. was a privately held biotechnology company founded in 2006 by Michael Gilman in Cambridge, Massachusetts, focused on developing innovative therapies for fibrosis and organ failure. The company's lead program was STX-100, an integrin αvβ6 inhibitor originally licensed from Biogen Idec, targeting idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Stromedix raised $25 million in venture funding and advanced STX-100 into clinical development before being acquired by Biogen Idec in March 2012 for $75 million upfront plus up to $487.5 million in milestone payments, valuing the deal at up to $562.5 million. The acquisition brought Stromedix's fibrosis pipeline into Biogen's research organization, where Gilman subsequently served as Executive Vice President of Research.